Ventrus Biosciences (NASDAQ:ASMB)

CAPS Rating: 2 out of 5

Recs

1
Player Avatar zzlangerhans (99.69) Submitted: 11/7/2012 11:38:11 PM : Outperform Start Price: $2.63 ASMB Score: +20.20

Ventrus struck out with hemorrhoids so now they're trying their luck with anal fissures. They've reported positive results from one phase III trial of VEN307 and the second is under way, but results aren't expected until Q4 2013 which means the PDUFA won't be until the end of 2014 at the earliest. Of course, there will be another dilutive financing at some point and the question is if the stock will be able to rebound a little before that becomes necessary. I think there's a good chance it will, but I wouldn't bet your ass on it.

Member Avatar jspendmd1 (< 20) Submitted: 12/13/2012 6:45:21 PM
Recs: 0

ZZ, that is sick. But cute.

Featured Broker Partners


Advertisement